A detailed history of Charles Schwab Investment Management Inc transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 724,241 shares of CRSP stock, worth $29.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
724,241
Previous 717,606 0.92%
Holding current value
$29.5 Million
Previous $38.8 Million 12.19%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$44.62 - $62.75 $296,053 - $416,346
6,635 Added 0.92%
724,241 $34 Million
Q2 2024

Aug 12, 2024

BUY
$51.17 - $68.18 $2.48 Million - $3.3 Million
48,414 Added 7.23%
717,606 $38.8 Million
Q1 2024

May 08, 2024

BUY
$60.67 - $89.12 $980,973 - $1.44 Million
16,169 Added 2.48%
669,192 $45.6 Million
Q4 2023

Feb 06, 2024

BUY
$38.62 - $72.18 $582,582 - $1.09 Million
15,085 Added 2.36%
653,023 $40.9 Million
Q3 2023

Nov 08, 2023

SELL
$45.39 - $59.0 $398,206 - $517,607
-8,773 Reduced 1.36%
637,938 $29 Million
Q2 2023

Aug 09, 2023

BUY
$43.47 - $67.77 $257,950 - $402,147
5,934 Added 0.93%
646,711 $36.3 Million
Q1 2023

May 11, 2023

SELL
$41.0 - $56.12 $12,997 - $17,790
-317 Reduced 0.05%
640,777 $29 Million
Q4 2022

Feb 13, 2023

BUY
$39.19 - $65.67 $743,669 - $1.25 Million
18,976 Added 3.05%
641,094 $26.1 Million
Q3 2022

Nov 14, 2022

BUY
$61.1 - $83.78 $16.7 Million - $23 Million
273,995 Added 78.71%
622,118 $40.7 Million
Q2 2022

Aug 15, 2022

SELL
$43.23 - $73.83 $288,776 - $493,184
-6,680 Reduced 1.88%
348,123 $21.2 Million
Q1 2022

May 13, 2022

BUY
$53.19 - $79.24 $18.9 Million - $28.1 Million
354,803 New
354,803 $22.3 Million

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.18B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.